



At Euretina'09, Critical Health Showcases a Breakthrough in Predicting Diabetic Retinopathy Progression

Critical Health (Booth C3) Launches Innovative Diabetic Retinopathy Progression Biomarker Software Solution, RetmarkerDR, in the European Market

Critical Health Partner AIBILI Presents Related Research at the 9th Euretina Congress

Coimbra, Portugal, May 14th, 2009 – Critical Health will be launching **RetmarkerDR**, an innovative Diabetic Retinopathy (DR) progression biomarker software in the European market at the Euretina exhibition (Booth C3; 14th to 17th May; Acropolis Centre; Nice; France). Critical Health is a leading provider of innovative products that help prevent the loss of vision, mobility and cognitive skills in an ageing population,

Also at the 9th Euretina Congress, leading researchers from Critical Health's partner AIBILI (Association for Biomedical Research and Innovation in Light and Image), will be presenting new research results that support this breakthrough in predicting Diabetic Retinopathy progression.

On the 14th of May, at Session 1 - Imaging to Monitor Progression, Professor Cunha-Vaz, AIBILI, will be presenting "The importance of monitoring progression in the early stages of retinal disease", to be followed by Professor Bernardes, Director of the Center of New Technologies for Medicine – AIBILI, regarding "Retmarker. Identifying progression on fundus images".

The RetmarkerDR software solution is a breakthrough in predicting Diabetic Retinopathy progression from a Nonproliferative stage to Clinically Significant Macular Edema (CSME), a sight-threatening stage. The solution is based on the latest research on Microaneurysm Turnover, the new and most reliable biomarker of Diabetic Retinopathy progression.

"This solution will become a critical tool to support ophthalmologists worldwide in the search for optimal management of diabetic retinopathy progression", said Ricardo Cunha-Vaz, Critical Health's CEO. "RetmarkerDR helps to deliver quality care and to reduce total healthcare spending by increasing the healthcare provider's productivity and reliability in the management of Diabetic Retinopathy and other retinal diseases".



The **RetmarkerDR** solution underlying approach is supported by recent leading edge research being presented by AIBILI at the most important scientific forums. Recently, two scientific papers supporting the **RetmarkerDR** technology were accepted for publication in the Ophthalmologica magazine and posters were presented at ARVO, in Fort Lauderdale, Florida, USA. The main conclusions of these studies are: Microaneurysm Turnover (more than just MA count) is a key indicator for the progression of Diabetic Retinopathy. **RetmarkerDR** is a reliable software tool which can be used to capture the MA turnover in the initial stages of DR.

For more information please visits www.retmarker.com

End.

About Critical Health

*Critical Health (www.critical-health.com) is a leading provider of innovative products that help prevent the loss of vision, mobility and cognitive skills in an ageing population. Critical Health's first solution is the Retmarker, available in two product versions. **RetmarkerC** provides a quick assessment of retinal changes over time and **RetmarkerDR** enables ophthalmologists to manage diabetic retinopathy progression.*

Critical Health is a spin-off of Critical Software's healthcare technology division. Critical Software (www.critical-software.com) is a successful European IT services company specializing in business and mission critical systems for defense, aerospace and telecommunications with solid reputation for software reliability (CMMI-3, ISO9001, Spice). Critical Health innovative solutions are driven by key partnerships with prestigious universities, hospitals and scientific institutions. For more information: info-cht@critical-health.com

For more information:

*Carlos Taveira
Get Global, Marketing Communications Consultancy
+351 213502551
+351 918711884
Email: carlos.taveira@getglobal.pt*